Cyberattacks against accounting software firm Wolters Kluwer and the City of Baltimore in May showed how the newest wave of malicious hacking can have significant, often...Technologyread more
The European parliamentary election is the second largest democratic exercise in the world.Europe Newsread more
Buybacks have gotten a bad rap from both Republicans and Democrats. But stocks would be trading at a massive discount without them.Marketsread more
Biden had criticized Kim Jong Un as a "dictator" and a "tyrant" at a recent rally in Philadelphia. North Korean state media responded by calling Biden a "fool of low IQ" among...Politicsread more
Fiat Chrysler and France's Renault could soon partner up to take on the sweeping changes to the global auto industry, according to a report in the Financial Times. The...Autosread more
Microsoft shares have gained 133% since November 2015, outperforming a tech "basket of unicorns" over that stretch.Technologyread more
The president's state visit comes amid tensions with carmaker Toyota over potential auto tariffs. Trump has repeatedly threatened Japanese and European carmakers with tariffs.Traderead more
The IRS is about to release a new draft of Form W-4, which will more closely reflect the changes stemming from the Tax Cuts and Jobs Act. For workers, that means they'll need...Personal Financeread more
The Mega Millions jackpot has spilled over $400 million. It would be the ninth largest winning since the game began in 2002.Personal Financeread more
Trump was speaking at a meeting of Japanese business leaders in Tokyo during his state visit to Japan on Saturday.Marketsread more
The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
IRVINE, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Praxsyn Corporation's (OTCQB:PXYN) wholly owned subsidiary, Mesa Pharmacy Inc. (Mesa), entered into a Business Associate Agreement with Products for Doctors for marketing and other services on January 23, 2015. The non-exclusive agreement between Products for Doctors and Mesa facilitates the marketing of Mesa's products to medical providers throughout California.
"After our first meeting with the executive team at Mesa Pharmacy, we knew that we wanted to join their team," said James Bradford, Executive Partner, Products for Doctors. "Mesa is a breath of fresh air for the pharmaceutical industry and we are thrilled to be working with such an accountable and passionate team."
"We are excited to be working with a family-oriented company like our own who believe integrity and transparency are key factors in creating a prosperous business," said Kelly Reynolds, CEO, Mesa Pharmacy.
Products for Doctors was established in 2013 when partners, James Bradford and Richard Valenta, saw the need for a non-narcotic approach to medicine. The partners began a physicians practice enhancement firm in order to help physicians provide better patient care, while also enhancing revenue for its clients. Since 2013, Products for Doctors has experienced significant growth, lending to its highly regarded reputation.
About Praxsyn Corporation
Headquartered in Irvine, California, Praxsyn works to realize the vision of medical professionals to improve the lives of patients. Mesa Pharmacy, a wholly owned subsidiary, provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and medical clinics. Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek for their patients. Additional company information can be found at www.praxsyn.com.
Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) including but not limited to statements regarding the past performance and anticipated results of the business associate agreement with Products for Doctors, Inc. and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.
CONTACT: Media/Investor Contact: IR@PraXsyn.com 949-777-6112 ext 101